Solara's Q4 FY26 earnings call transcript highlights ongoing strategic review of the ibuprofen business, with a potential update expected in H1 FY27 and no backward integration for inputs.
AI Assistant
Solara Active Pharma Sciences Ltd
2026
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.